EU Urged on Pandemic Equity
Analysis based on 10 articles · First reported Mar 18, 2026 · Last updated Mar 20, 2026
The ongoing negotiations for the WHO Pandemic Agreement, particularly the Pathogen Access and Benefit Sharing (PABS) Annex, have significant implications for the global pharmaceutical and biotechnology markets. Equitable access provisions could lead to increased manufacturing and distribution opportunities in developing countries, potentially impacting the market dominance of major pharmaceutical companies in the Global North. The push for local vaccine production in nations like Nigeria could also shift market dynamics and investment flows in the healthcare sector.
The AIDS Healthcare Foundation (AHF) Nigeria and other Civil Society Organisations (CSOs) are urging the European Union (EU) to support health equity in the ongoing World Health Organization (WHO) Pandemic Agreement negotiations. They warn that a weak Pathogen Access and Benefit-Sharing (PABS) Annex could lead to a repeat of 'vaccine apartheid' experienced during the COVID-19 pandemic. Key figures like Echey Ijezie of AHF, Romy Mum of Lawyers Alert, and Martin Egbanubi of JOHESU are advocating for mandatory benefit-sharing, legal certainty, and real accountability, emphasizing that developing countries demand binding rules over voluntary arrangements. The deadline for the PABS Annex ratification is May 2026, and failure to secure a binding agreement risks delaying the entire Pandemic Agreement and undermining efforts to build regional manufacturing capacity and health sovereignty in low- and middle-income countries. The advocacy efforts are focused on the EU due to its pivotal role in the negotiations, with a shift in its position potentially breaking the current deadlock and ensuring a more equitable global pandemic agreement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard